Cell Cycle News and Research

RSS

Tobacco-free cigarettes may be more carcinogenic than tobacco products: Study

Using the same technique they developed to document the harmful effects of tobacco products, a team of researchers found that cigarettes made without tobacco or nicotine may be more carcinogenic because they actually induce more extensive DNA damage than tobacco products.

13 May 2010

MicroStockProfit.com features investment report on ARIAD Pharmaceuticals

MicroStockProfit.com announces an investment report featuring ARIAD Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

10 May 2010

Researchers demonstrate how Plasmodium falciparum can able to circumvent action of artemisinin

Researchers from CNRS, INSERM and Toulouse University Hospital have demonstrated how the parasite Plasmodium falciparum, which causes severe forms of malaria, is able to circumvent the action of artemisinin and its derivatives, which are today the first-line drugs used to treat this disease. This study supplies some important findings that will enable a clearer understanding of the mechanisms of resistance to antimalarial drugs and the testing of novel therapeutic strategies in a context where the drug resistance of parasites is of increasing concern.

6 May 2010

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid.

3 May 2010

Poster on dual Erk/PI3K inhibitors presented at AACR 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today presented a poster on dual Erk/PI3K inhibitors and made an oral presentation on its selective Erk inhibitors, at the American Association for Cancer Research Annual Meeting in Washington, D.C.

21 Apr 2010

New treatment modalities for RCC

Renal cell carcinoma accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

21 Apr 2010

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

In the first study of vitamin K and Non-Hodgkin lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing Non-Hodgkin lymphoma.

20 Apr 2010

Surgery still the only measure to cure RCC

Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

19 Apr 2010

New p53 knockout rat model improves timelines for carcinogenicity screening

Sigma Life Science, the innovative biological products and services brand of Sigma-Aldrich, today introduced the world's first p53 'knockout' rat model, an important development that is expected to, due to the rat's closer physiological and metabolic similarity to humans, significantly improve timelines for carcinogenicity screening and reduce time to market for therapeutics.

19 Apr 2010

Tumor suppressor, Retinoblastoma, represses DNA replication genes during cellular senescence

A frequently mutated gene in human cancers is the reitnoblastoma (RB) gene, which controls a potent tumor suppression pathway.

15 Apr 2010

Src can be most promising targets for cancer therapy

Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. Src represents one of the most promising targets for cancer therapy.

6 Apr 2010

Cyclacel Pharmaceuticals' abstracts on cell cycle inhibitor drugs selected for presentation at AACR meeting

Cyclacel Pharmaceuticals, Inc. today announced that six abstracts highlighting translational and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC.

2 Apr 2010

Working of master regulator protein phosphatase 1

Protein phosphorylation is a process by which proteins are flipped from one activation state to another. It is a crucial function for most living beings, since phosphorylation controls nearly every cellular process, including metabolism, gene transcription, cell-cycle progression, cytoskeletal rearrangement and cell movement.

26 Mar 2010

Study on zebrafish regenerate tissues links human heart implications

In a paper published in the March 25, 2010 issue of Nature, researchers working at the Salk Institute for Biological Studies and the Center of Regenerative Medicine in Barcelona (CMRB) identified a fish heart cell population that is the source of this astonishing healing feat, a finding that could provide insight into how mammalian hearts might be coaxed into repairing themselves after injury brought on by heart attack.

25 Mar 2010

Microbiology of the oceans, gut microbes and STIs to be discussed at SGM spring meeting 2010

Microbiology of the oceans, gut microbes and STIs are just some of the topics reflecting modern microbial science that will be covered next week at the Society for General Microbiology's spring meeting 2010.

23 Mar 2010

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

18 Mar 2010

Novel findings point to new therapeutic approaches for common types of cancer

Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.

18 Mar 2010

New findings promise to have fundamental significance in the fight against cancer

Cells have two different protection programs to safeguard them from getting out of control under stress and from dividing without stopping and developing cancer. Until now, researchers assumed that these protective systems were prompted separately from each other.

18 Mar 2010

Glycolytic oscillations during ischemia can increase heart damage

Researchers in Germany show that a classical biological oscillator, the glycolytic oscillator, may increase damage to the heart during acute loss of oxygen (anoxia), and as may occur during ischemia.

16 Mar 2010

Study supports Myriad Genetics' PROLARIS molecular diagnostic test for predicting prostate cancer recurrence

Myriad Genetics, Inc. today said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS™, was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco. The abstract of the presentation entitled: "Cell Cycle Genes Predict Recurrence After Radical Prostatectomy" by Gregory P. Swanson, M.D., University of Texas Health Science Center San Antonio, and colleagues is now available on the American Society of Clinical Oncology's website, www.asco.org.

11 Mar 2010

Cell Cycle News and Research

Tobacco-free cigarettes may be more carcinogenic than tobacco products: Study

MicroStockProfit.com features investment report on ARIAD Pharmaceuticals

Researchers demonstrate how Plasmodium falciparum can able to circumvent action of artemisinin

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Poster on dual Erk/PI3K inhibitors presented at AACR 2010

New treatment modalities for RCC

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

Surgery still the only measure to cure RCC

New p53 knockout rat model improves timelines for carcinogenicity screening

Tumor suppressor, Retinoblastoma, represses DNA replication genes during cellular senescence

Src can be most promising targets for cancer therapy

Cyclacel Pharmaceuticals' abstracts on cell cycle inhibitor drugs selected for presentation at AACR meeting

Working of master regulator protein phosphatase 1

Study on zebrafish regenerate tissues links human heart implications

Microbiology of the oceans, gut microbes and STIs to be discussed at SGM spring meeting 2010

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

Novel findings point to new therapeutic approaches for common types of cancer

New findings promise to have fundamental significance in the fight against cancer

Glycolytic oscillations during ischemia can increase heart damage

Study supports Myriad Genetics' PROLARIS molecular diagnostic test for predicting prostate cancer recurrence

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News